Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anthony A. Estrada is active.

Publication


Featured researches published by Anthony A. Estrada.


Science Translational Medicine | 2012

Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations

Zejuan Sheng; Shuo Zhang; Daisy Bustos; Tracy Kleinheinz; Claire E. Le Pichon; Sara L. Dominguez; Hilda Solanoy; Jason Drummond; Xiaolin Zhang; Xiao Ding; Fang Cai; Qinghua Song; Xianting Li; Zhenyu Yue; Marcel van der Brug; Daniel J. Burdick; Janet Gunzner-Toste; Huifen Chen; Xingrong Liu; Anthony A. Estrada; Zachary Kevin Sweeney; Kimberly Scearce-Levie; John Moffat; Donald S. Kirkpatrick; Haitao Zhu

LRRK2 autophosphorylation on Ser1292 may be a useful indicator of kinase activity, providing a readout for screening candidate LRRK2 inhibitors. LRRK2 Inhibitor Heralds a Happier Song Genetic polymorphisms in the leucine-rich repeat kinase 2 (LRRK2) are the most common causes of familial Parkinson’s disease (PD) and are also linked to idiopathic PD. The most prevalent LRRK2 PD mutation G2019S imbues the kinase with a gain of function, suggesting that blocking LRRK2 activity may be a therapeutic strategy for reversing the pathogenic effects of LRRK2 mutations in PD. However, the mechanistic link between LRRK2 kinase activity and the cellular effects of PD mutations remains elusive, and there has been no reliable way to monitor LRRK2 kinase activity in vivo. Using quantitative mass spectrometry and subsequent phospho-specific antibody approaches, Sheng et al. now report that LRRK2 phosphorylates itself on Ser1292 in vitro and in vivo (Ser1292 autophosphorylation). Five of the six confirmed familial LRRK2 PD mutations increased Ser1292 autophosphorylation when transiently expressed in heterologous cells, suggesting increased Ser1292 autophosphorylation as a common feature of LRRK2 PD mutations. Elimination of the Ser1292 autophosphorylation site abrogated the defects on neurite outgrowth caused by LRRK2 PD mutations in cultured rat embryonic neurons. Using Ser1292 autophosphorylation as the readout of kinase activity, Sheng et al. developed assays to monitor LRRK2 kinase activity in cultured cells and rodents. These assays were used to profile the potencies of hundreds of LRRK2 kinase inhibitors derived from high-throughput compound screening. A potent and selective compound that effectively inhibited LRRK2 kinase activity in mouse brains and reversed cellular effects of LRRK2 PD mutations in cultured primary neurons was identified. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of familial Parkinson’s disease (PD). Although biochemical studies have shown that certain PD mutations confer elevated kinase activity in vitro on LRRK2, there are no methods available to directly monitor LRRK2 kinase activity in vivo. We demonstrate that LRRK2 autophosphorylation on Ser1292 occurs in vivo and is enhanced by several familial PD mutations including N1437H, R1441G/C, G2019S, and I2020T. Combining two PD mutations together further increases Ser1292 autophosphorylation. Mutation of Ser1292 to alanine (S1292A) ameliorates the effects of LRRK2 PD mutations on neurite outgrowth in cultured rat embryonic primary neurons. Using cell-based and pharmacodynamic assays with phosphorylated Ser1292 as the readout, we developed a brain-penetrating LRRK2 kinase inhibitor that blocks Ser1292 autophosphorylation in vivo and attenuates the cellular consequences of LRRK2 PD mutations in vitro. These data suggest that Ser1292 autophosphorylation may be a useful indicator of LRRK2 kinase activity in vivo and may contribute to the cellular effects of certain PD mutations.


Journal of Medicinal Chemistry | 2012

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

Anthony A. Estrada; Xingrong Liu; Charles Baker-Glenn; Alan Beresford; Daniel J. Burdick; Mark Stuart Chambers; Bryan K. Chan; Huifen Chen; Xiao Ding; Antonio G. DiPasquale; Sara L. Dominguez; Jennafer Dotson; Jason Drummond; Michael Flagella; Sean P. Flynn; Reina N. Fuji; Andrew Gill; Janet Gunzner-Toste; Seth F. Harris; Timothy P. Heffron; Tracy Kleinheinz; Donna W. Lee; Claire E. Le Pichon; Joseph P. Lyssikatos; Andrew D. Medhurst; John Moffat; Susmith Mukund; Kevin Nash; Kimberly Scearce-Levie; Zejuan Sheng

There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinsons disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligand efficient aminopyrimidine lead compounds. High throughput in vivo rodent cassette pharmacokinetic studies enabled rapid validation of in vitro-in vivo correlations. Guided by this data, optimal design parameters were established. Effective incorporation of these guidelines into our molecular design process resulted in the discovery of small molecule inhibitors such as GNE-7915 (18) and 19, which possess an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species. Advancement of GNE-7915 into rodent and higher species toxicity studies enabled risk assessment for early development.


Science Translational Medicine | 2015

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

Reina N. Fuji; Michael Flagella; Miriam Baca; Marco A. S. Baptista; Jens Brodbeck; Bryan K. Chan; Brian K. Fiske; Lee Honigberg; Adrian M. Jubb; Paula Katavolos; Donna W. Lee; Sock-Cheng Lewin-Koh; Tori Lin; Xingrong Liu; Shannon Liu; Joseph P. Lyssikatos; Jennifer O'Mahony; Mike Reichelt; Merone Roose-Girma; Zejuan Sheng; Todd Sherer; Ashley Smith; Margaret Solon; Zachary Kevin Sweeney; Jacqueline M. Tarrant; Alison Urkowitz; Søren Warming; Murat Yaylaoglu; Shuo Zhang; Haitao Zhu

LRRK2 kinase inhibitors, under development for Parkinson’s disease, have an effect on type II pneumocytes in nonhuman primate lung, suggesting that pulmonary toxicity may be a critical safety liability. A lung phenotype for LRRK2 inhibitors Human genetic evidence implicates leucine-rich repeat kinase 2 (LRRK2) as a high-priority drug target for Parkinson’s disease. However, the benefit and risk of inhibiting the kinase activity of LRRK2 is unknown and is currently untested in humans. Using two selective LRRK2 kinase inhibitors, Fuji et al. report a safety liability in nonhuman primates characterized by morphological changes in lung. These results are consistent with observations in mice lacking LRRK2. These safety observations offer a cautionary note for pharmacological modulation of LRRK2 in humans. Inhibition of the kinase activity of leucine-rich repeat kinase 2 (LRRK2) is under investigation as a possible treatment for Parkinson’s disease. However, there is no clinical validation as yet, and the safety implications of targeting LRRK2 kinase activity are not well understood. We evaluated the potential safety risks by comparing human and mouse LRRK2 mRNA tissue expression, by analyzing a Lrrk2 knockout mouse model, and by testing selective brain-penetrating LRRK2 kinase inhibitors in multiple species. LRRK2 mRNA tissue expression was comparable between species. Phenotypic analysis of Lrrk2 knockout mice revealed morphologic changes in lungs and kidneys, similar to those reported previously. However, in preclinical toxicity assessments in rodents, no pulmonary or renal changes were induced by two distinct LRRK2 kinase inhibitors. Both of these kinase inhibitors induced abnormal cytoplasmic accumulation of secretory lysosome-related organelles known as lamellar bodies in type II pneumocytes of the lung in nonhuman primates, but no lysosomal abnormality was observed in the kidney. The pulmonary change resembled the phenotype of Lrrk2 knockout mice, suggesting that this was LRRK2-mediated rather than a nonspecific or off-target effect. A biomarker of lysosomal dysregulation, di-docosahexaenoyl (22:6) bis(monoacylglycerol) phosphate (di-22:6-BMP), was also decreased in the urine of Lrrk2 knockout mice and nonhuman primates treated with LRRK2 kinase inhibitors. Our results suggest a role for LRRK2 in regulating lysosome-related lamellar bodies and that pulmonary toxicity may be a critical safety liability for LRRK2 kinase inhibitors in patients.


Journal of Medicinal Chemistry | 2012

Discovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular Modeling

Huifen Chen; Bryan K. Chan; Jason Drummond; Anthony A. Estrada; Janet Gunzner-Toste; Xingrong Liu; Yichin Liu; John Moffat; Daniel Shore; Zachary Kevin Sweeney; Thuy Tran; Shumei Wang; Guiling Zhao; Haitao Zhu; Daniel J. Burdick

Mutations in the genetic sequence of leucine-rich repeat kinase 2 (LRRK2) have been linked to increased LRRK2 activity and risk for the development of Parkinsons disease (PD). Potent and selective small molecules capable of inhibiting the kinase activity of LRRK2 will be important tools for establishing a link between the kinase activity of LRRK2 and PD. In the absence of LRRK2 kinase domain crystal structures, a LRRK2 homology model was developed that provided robust guidance in the hit-to-lead optimization of small molecule LRRK2 inhibitors. Through a combination of molecular modeling, sequence analysis, and matched molecular pair (MMP) activity cliff analysis, a potent and selective lead inhibitor was discovered. The selectivity of this compound could be understood using the LRRK2 homology model, and application of this learning to a series of 2,4-diaminopyrimidine inhibitors in a scaffold hopping exercise led to the identification of highly potent and selective LRRK2 inhibitors that were also brain penetrable.


Journal of Medicinal Chemistry | 2014

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

Anthony A. Estrada; Bryan K. Chan; Charles Baker-Glenn; Alan Beresford; Daniel J. Burdick; Mark Stuart Chambers; Huifen Chen; Sara L. Dominguez; Jennafer Dotson; Jason Drummond; Michael Flagella; Reina N. Fuji; Andrew Gill; Jason S. Halladay; Seth F. Harris; Timothy P. Heffron; Tracy Kleinheinz; Donna W. Lee; Claire E. Le Pichon; Xingrong Liu; Joseph P. Lyssikatos; Andrew D. Medhurst; John Moffat; Kevin Nash; Kimberly Scearce-Levie; Zejuan Sheng; Daniel Shore; Susan Wong; Shuo Zhang; Xiaolin Zhang

Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinsons disease therapy. Herein, we disclose structurally diverse small molecule inhibitors suitable for assessing the implications of sustained in vivo LRRK2 inhibition. Using previously reported aminopyrazole 2 as a lead molecule, we were able to engineer structural modifications in the solvent-exposed region of the ATP-binding site that significantly improve human hepatocyte stability, rat free brain exposure, and CYP inhibition and induction liabilities. Disciplined application of established optimal CNS design parameters culminated in the rapid identification of GNE-0877 (11) and GNE-9605 (20) as highly potent and selective LRRK2 inhibitors. The demonstrated metabolic stability, brain penetration across multiple species, and selectivity of these inhibitors support their use in preclinical efficacy and safety studies.


Journal of Medicinal Chemistry | 2015

Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models

Snahel Patel; Fred E. Cohen; Brian Dean; Kelly De La Torre; Gauri Deshmukh; Anthony A. Estrada; Arundhati Sengupta Ghosh; Paul Gibbons; Amy Gustafson; Malcolm P. Huestis; Claire E. Le Pichon; Han Lin; Wendy Liu; Xingrong Liu; Yichin Liu; Cuong Ly; Joseph P. Lyssikatos; Changyou Ma; Kimberly Scearce-Levie; Young G. Shin; Hilda Solanoy; Kimberly L. Stark; Jian Wang; Bei Wang; Xianrui Zhao; Joseph W. Lewcock; Michael Siu

Dual leucine zipper kinase (DLK, MAP3K12) was recently identified as an essential regulator of neuronal degeneration in multiple contexts. Here we describe the generation of potent and selective DLK inhibitors starting from a high-throughput screening hit. Using proposed hinge-binding interactions to infer a binding mode and specific design parameters to optimize for CNS druglike molecules, we came to focus on the di(pyridin-2-yl)amines because of their combination of desirable potency and good brain penetration following oral dosing. Our lead inhibitor GNE-3511 (26) displayed concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease. These results suggest that specific pharmacological inhibition of DLK may have therapeutic potential in multiple indications.


Journal of Medicinal Chemistry | 2013

Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR)

Anthony A. Estrada; Daniel Shore; Elizabeth Blackwood; Yung-Hsiang Chen; Gauri Deshmukh; Xiao Ding; Antonio G. DiPasquale; Jennifer Epler; Lori Friedman; Michael F. T. Koehler; Lichuan Liu; Shiva Malek; Jim Nonomiya; Daniel F. Ortwine; Zhonghua Pei; Steve Sideris; Frederic St-Jean; Lan Trinh; Tom Truong; Joseph P. Lyssikatos

We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve aqueous solubility and oral absorption, reduce free drug clearance, and selectively increase mTOR potency. Through key in vitro and in vivo studies, we demonstrate that a pyrimidoaminotropane based core was able to address each of these goals. This effort culminated in the discovery of 20 (GNE-555), a highly potent, selective, metabolically stable, and efficacious mTOR inhibitor.


ACS Medicinal Chemistry Letters | 2013

Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor

Bryan K. Chan; Anthony A. Estrada; Huifen Chen; John Atherall; Charles Baker-Glenn; Alan Beresford; Daniel J. Burdick; Mark Stuart Chambers; Sara L. Dominguez; Jason Drummond; Andrew Gill; Tracy Kleinheinz; Claire E. Le Pichon; Andrew D. Medhurst; Xingrong Liu; John Moffat; Kevin Nash; Kimberly Scearce-Levie; Zejuan Sheng; Daniel Shore; Hervé Van de Poël; Shuo Zhang; Haitao Zhu; Zachary Kevin Sweeney

The modulation of LRRK2 kinase activity by a selective small molecule inhibitor has been proposed as a potentially viable treatment for Parkinsons disease. By using aminopyrazoles as aniline bioisosteres, we discovered a novel series of LRRK2 inhibitors. Herein, we describe our optimization effort that resulted in the identification of a highly potent, brain-penetrant aminopyrazole LRRK2 inhibitor (18) that addressed the liabilities (e.g., poor solubility and metabolic soft spots) of our previously disclosed anilino-aminopyrimidine inhibitors. In in vivo rodent PKPD studies, 18 demonstrated good brain exposure and engendered significant reduction in brain pLRRK2 levels post-ip administration. The strategies of bioisosteric substitution of aminopyrazoles for anilines and attenuation of CYP1A2 inhibition described herein have potential applications to other drug discovery programs.


ACS Medicinal Chemistry Letters | 2013

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

Zhonghua Pei; Elizabeth Blackwood; Lichuan Liu; Shiva Malek; Marcia Belvin; Michael F. T. Koehler; Daniel F. Ortwine; Huifen Chen; Fred E. Cohen; Jane R. Kenny; Philippe Bergeron; Kevin Lau; Cuong Ly; Xianrui Zhao; Anthony A. Estrada; Tom Truong; Jennifer Epler; Jim Nonomiya; Lan Trinh; Steve Sideris; John D. Lesnick; Linda Bao; Ulka Vijapurkar; Sophie Mukadam; Suzanne Tay; Gauri Deshmukh; Yung-Hsiang Chen; Xiao Ding; Lori Friedman; Joseph P. Lyssikatos

Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.


Journal of Medicinal Chemistry | 2015

Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors

Anthony A. Estrada; Zachary Kevin Sweeney

There is an urgent need for the development of Parkinsons disease (PD) treatments that can slow disease progression. The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to PD, and modulation of LRRK2 enzymatic activity has been proposed as a novel therapeutic strategy. In this review, we describe the bioactivity of selected small molecules that have been used to inhibit LRRK2 kinase activity in vitro or in vivo. These compounds are important tools for understanding the cellular biology of LRRK2 and for evaluating the potential of LRRK2 inhibitors as disease-modifying PD therapies.

Collaboration


Dive into the Anthony A. Estrada's collaboration.

Researchain Logo
Decentralizing Knowledge